Indegene Q3 net profit flat as one‑time costs, amortization offset 31% revenue jump

Manish Gupta, CEO Indegene Ltd

Indegene Ltd. on Friday reported a largely unchanged year-on-year (YoY) net profit for Q3FY26 despite delivering its first‑ever $100‑million quarter, as one‑time expenses and higher amortization weighed on the bottom line.

Profit after tax came in at Rs 102.6 crore, nearly flat sequentially and down 6.5 percent year‑on‑year, even as revenue rose 30.8 percent YoY to Rs 942.1 crore.

The company said profitability was tempered by Rs 10.5 crore in one‑time expenses and elevated non‑cash amortization linked to recently completed acquisitions. Interest income also fell sharply.

CFO Suhas Prabhu said these impacts were temporary and would ease as integration synergies flow through.

Adjusted EBITDA rose 15.7 percent YoY to Rs 174.7 crore, with margins at 18.5 percent.

CEO Manish Gupta said the quarter marked “a standout performance,” highlighting that revenue per employee crossed $70,000, the highest in the industry, driven by AI‑enabled productivity.

Indegene closed two acquisitions—US‑based BioPharm and UK‑based Warn & Co.—expanding its omnichannel and consulting capabilities. Cash and investments stood at Rs 1,395.4 crore post‑acquisition outflows.

Client metrics continued to strengthen, with three of the top five customers now contributing over $25 million annually, and 52 accounts exceeding $1 million in annual revenue. New deal wins included two contracts above $10 million in ACV.

The company said profitability should improve in coming quarters as one‑time costs normalize and amortization stabilizes.